ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0552

Long Non-coding RNA H19X as a Regulator of Endothelial Adhesion Molecules in Systemic Sclerosis

Francesca Tirelli1, Elena Pachera1, Robert Lafyatis2, Menqi Huang3, Francesco Zulian4, Gabriela Kania1 and Oliver Distler5, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, 2University of Pittsburgh, Pittsburgh, PA, 3Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 4Rheumatology Unit, Department of Woman and Child Health - University of Padova, Padova, Italy, 5Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland

Meeting: ACR Convergence 2021

Keywords: Adhesion, Adhesion molecules, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Systemic Sclerosis & Related Disorders – Basic Science Poster (0541–0559)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Long non-coding RNAs (lncRNAs) are non-coding transcripts involved in the regulation of gene expression; their role in disease development, to date, remains largely under investigation. Recently, we showed that lncRNA H19X is pivotal in the regulation of TGFβ driven fibrosis in SSc. Here, we aimed to characterize the functional relevance of H19X in endothelial cell (EC) activation, a crucial mechanism in SSc vasculopathy.

Methods: Single-cell RNA-sequencing (scRNA-seq) was performed on 27 dcSSc and 10 healthy controls (HC) skin biopsies. After library preparation (10X Genomics protocol) and sequencing (Illumina NextSeq-500 platform), the reads were examined by quality metrics and transcripts mapped to reference human genome (GRCh38). Data analysis was performed using Seurat package in R (v. 3.0). A total of 4981 EC (1583 from HC and 3398 from SSc patients, 59-342 EC per subject), characterized by enrichment of EC markers of CLDN5, VWF and PECAM1, were identified and analyzed for the expression of H19X and specific EC activation markers. The function of H19X was analyzed in Human Dermal Microvascular EC (HDMEC). H19X expression was analyzed by qPCR after HDMEC stimulation with different proinflammatory cytokines at biologically relevant concentrations. HDMEC were transfected using locked nucleic acid antisense oligonucleotides (LNA GapmeRs). Western Blot (WB) and qPCR were used to analyze the effects of H19X silencing on endothelial adhesion molecules.

Results: scRNA-seq data from skin biopsies showed a significant upregulation of H19X in SSc compared to healthy EC (p=0.0095), which was observed also for various EC subclusters. Identified subclusters included arterial (characterized by SEMA3G, HEY1), capillary (CA4, RGCC), venous (ACKR1, VCAM1) and lymphatic (PROX1, LYVE1) EC. Two additional clusters, proliferating (TOP2A, MKI67) and injured (HSGP2, APLNR) EC, were represented almost exclusively in SSc ECs. Specifically, the highest expression of H19X was found in injured SSc EC and capillary SSc EC. Overall, 1.5% of the SSc EC, about 51 cells, expressed detectable levels of H19X. In HDMEC (n=3), H19X was consistently induced by IFNα, IFNβ and IFNγ as well as by different IFN combination stimulations (IFNα+β+γ and α+γ). Time curve analysis demonstrated that the strongest induction was observed between 48h and 72h. Importantly, H19X knockdown lead to a consistent and significant decrease of mRNAs of the adhesion molecule VCAM1, both in untreated HDMEC (n=4, p=0.006) as well as after IFN stimulation. A decrease of VCAM1 could be also demonstrated by WB analysis (untreated, n=4, p=0.01, semiquantitative analysis). Furthermore, co-expression analysis of the scRNA-seq data from skin biopsies confirmed a higher expression of several adhesion molecules in EC expressing H19X, including ICAM, VCAM1 and JAM3.

Conclusion: H19X is overexpressed in SSc endothelium and is stimulated by IFNs. Our results point to a role of H19X as a regulator of adhesion molecules in EC, thus suggesting its potential involvement in the pathogenesis of SSc vasculopathy.


Disclosures: F. Tirelli, None; E. Pachera, None; R. Lafyatis, Bristol Meyers Squibb, 2, 5, Formation, 2, 5, Corbus, 5, Moderna, 5, Regeneron, 5, Pfizer, 5, Kiniksa, 5, Sanofi, 2, Merck, 2, Genentech/Roche, 2, Acceleron, 2, Boehringer-Ingelheim, 2; M. Huang, None; F. Zulian, None; G. Kania, None; O. Distler, AbbVie, 12, Project scoring fee for Rheumatology Grant, Amgen, 2, Eli Lilly, 2, Pfizer Inc, 2.

To cite this abstract in AMA style:

Tirelli F, Pachera E, Lafyatis R, Huang M, Zulian F, Kania G, Distler O. Long Non-coding RNA H19X as a Regulator of Endothelial Adhesion Molecules in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/long-non-coding-rna-h19x-as-a-regulator-of-endothelial-adhesion-molecules-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-non-coding-rna-h19x-as-a-regulator-of-endothelial-adhesion-molecules-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology